Literature DB >> 9468237

The outpatient evaluation of hematochezia.

W N Segal1, P D Greenberg, D C Rockey, J P Cello, K R McQuaid.   

Abstract

OBJECTIVE: The objective of this study was to determine whether specific clinical symptoms associated with hematochezia are predictive of important GI pathology and whether full colonoscopic examination is necessary.
METHODS: A total of 103 outpatients (> or = 45 yr) with hematochezia, defined as the passage of bright red blood per rectum, underwent anoscopy and colonoscopy. Before endoscopy, patients completed a detailed interview, quantitating the amount and frequency of bleeding, weight loss, use of aspirin/NSAIDs, change in bowel habits, family history, and prior GI illnesses. Based on this information, physicians were asked to predict whether the bleeding was from a perianal or more proximal site. At colonoscopy, pathology was stratified as either proximal or distal to the sigmoid/descending junction. Substantial pathology was defined as one or more adenomas > 8 mm, carcinoma, or colitis.
RESULTS: Anoscopy demonstrated internal and external hemorrhoids in 78 and 29 patients, respectively. On colonoscopy, 36 patients had 43 substantial lesions. Thirty-seven of these lesions were distal to the junction of the descending and sigmoid colons and six were proximal lesions. Four patients had cancer; all were distal lesions. Patients with substantial lesions were more likely to give a history of blood mixed within their stool (p = 0.03), to have more episodes of hematochezia per month (p = 0.008), and to have a significantly shorter duration of bleeding before medical evaluation (p = 0.02) than did patients without such lesions. However, the physician's clinical assessment did not predict reliably which patients were likely to have substantial pathology.
CONCLUSIONS: In patients with hematochezia, clinicians were unable to distinguish between those patients with and those without significant colonic lesions by history alone. Flexible sigmoidoscopy would have demonstrated most (95%) substantial lesions. The lesions that flexible sigmoidoscopy missed were an unlikely cause of bleeding in this small group of patients.

Entities:  

Mesh:

Year:  1998        PMID: 9468237     DOI: 10.1111/j.1572-0241.1998.00179.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Canadian consensus on medically acceptable wait times for digestive health care.

Authors:  William G Paterson; William T Depew; Pierre Paré; Denis Petrunia; Connie Switzer; Sander J Veldhuyzen van Zanten; Sandra Daniels
Journal:  Can J Gastroenterol       Date:  2006-06       Impact factor: 3.522

2.  Colonoscopic evaluation of hematochezia in low and average risk patients for colorectal cancer: a prospective study.

Authors:  Puglisi Carlo; Russo-Francesco Paolo; Barbera Carmelo; Incarbone Salvatore; Aprile Giuseppe; Bonanno Giacomo; Russo Antonio
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

3.  Endoscopy for hematochezia in patients under 50 years of age.

Authors:  J D Lewis; C E Shih; D Blecker
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

4.  The evaluation of rectal bleeding in adults. A cost-effectiveness analysis comparing four diagnostic strategies.

Authors:  Elizabeth Allen; Christina Nicolaidis; Mark Helfand
Journal:  J Gen Intern Med       Date:  2005-01       Impact factor: 5.128

Review 5.  Hematochezia in the young patient: a review of health-seeking behavior, physician attitudes, and controversies in management.

Authors:  Rashid Khan; David Hyman
Journal:  Dig Dis Sci       Date:  2009-02-24       Impact factor: 3.199

Review 6.  Interventional management of lower gastrointestinal bleeding.

Authors:  Derik T Weldon; Stephen J Burke; Shiliang Sun; Hidefumi Mimura; Jafar Golzarian
Journal:  Eur Radiol       Date:  2008-01-08       Impact factor: 5.315

7.  Short term outcome of patients with hematochezia and normal initial colonoscopic findings: do they really need further screening?

Authors:  S A Taghavi; S Sha Bani; M Khademalhoseini; N Shabanipour; A Mehramiri; S Negahban; S Yahyazadeh; A Eshraghian
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.